We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Crystal Research Associates, LLC Issues EIO on Convoy Therapeutics, Inc.
News

Crystal Research Associates, LLC Issues EIO on Convoy Therapeutics, Inc.

Crystal Research Associates, LLC Issues EIO on Convoy Therapeutics, Inc.
News

Crystal Research Associates, LLC Issues EIO on Convoy Therapeutics, Inc.

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Crystal Research Associates, LLC Issues EIO on Convoy Therapeutics, Inc."

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Convoy's innovative Skin-Penetrating-And-Cell-Entering (SPACE) Peptide Technology uses a family of proprietary peptide sequences to transport topical drug and cosmetic compounds into the skin. A key competitive advantage of the SPACE technology is that it can be used to administer both small and large molecules. Many biologic drugs and therapeutic proteins, among other macromolecules, cannot be effectively delivered through the skin with current technologies due to the size of the active molecule. The SPACE Peptide not only facilitates skin penetration of large molecules but has also been shown to retain small compounds in the skin, potentiating a longer-lasting treatment effect. The technology is non-invasive and has been found to be non-toxic.

Convoy's pipeline includes using the SPACE platform to reformulate a well-known oral and injectable therapeutic, cyclosporine A, into a topical treatment for psoriasis called CycloPsorb™, as well as creating a topical hyaluronic acid cosmetic compound to reduce fine lines/wrinkles as a supplement to dermal filler and Botox® injections.

Advertisement